Systematic biochemical analysis of somatic missense mutations in DNA polymerase [beta] found in prostate cancer reveal alteration of enzymatic function

DNA polymerase [beta] is essential for short-patch base excision repair. We have previously identified 20 somatic pol [beta] mutations in prostate tumors, many of them missense. In the current article we describe the effect of all of these somatic missense pol [beta] mutations (p.K27N, p.E123K, p.E232K, p.P242R, p.E216K, p.M236L, and the triple mutant p.P261L/T292A/I298T) on the biochemical properties of the polymerase in vitro, following bacterial expression and purification of the respective enzymatic variants. We report that all missense somatic pol [beta] mutations significantly affect enzyme function. Two of the pol [beta] variants reduce catalytic efficiency, while the remaining five missense mutations alter the fidelity of DNA synthesis. Thus, we conclude that a significant proportion (9 out of 26; 35%) of prostate cancer patients have functionally important somatic mutations of pol [beta]. Many of these missense mutations are clonal in the tumors, and/or are associated with loss of heterozygosity and microsatellite instability. These results suggest that interfering with normal polymerase [beta] function may be a frequent mechanism of prostate tumor progression. Furthermore, the availability of detailed structural information for pol [beta] allows understanding of the potential mechanistic effects of these mutants on polymerase function. Hum Mutat 32:1-9, 2011. © 2011 Wiley-Liss, Inc.